Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 2,745 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Systemic Clear all
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Systemic Absorption of Dexamethasone Oral Rinse in Patients With Oral Lichen Planus

NCT06428630
View directory record Official record
Conditions
Oral Lichen Planus, Oral Lichenoid Reaction
Interventions
dexamethasone oral rinse
Drug
Lead sponsor
Tufts University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 29, 2026, 5:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs

NCT02215122
View directory record Official record
Conditions
Asthma, COPD
Interventions
MGR001, Advair® Diskus®, Seretide™ Accuhaler™
Drug
Lead sponsor
Mylan Pharma UK Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Oct 29, 2026, 5:06 AM EDT
Active, not recruiting Phase 2 Interventional

Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)

NCT06843239
View directory record Official record
Conditions
Systemic Sclerosis (SSc), Scleroderma
Interventions
Tibulizumab, Placebo
Biological · Other
Lead sponsor
Zura Bio Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
La Jolla, California • Los Angeles, California • Plantation, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 29, 2026, 5:06 AM EDT
Completed Not applicable Interventional

HeRO Vascular Access Device Bacteremia Study

NCT00889564
View directory record Official record
Conditions
Hemodialysis
Interventions
HeRO Vascular Access Device
Device
Lead sponsor
Merit Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
Miami, Florida • Atlanta, Georgia • Springfield, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Oct 29, 2026, 5:06 AM EDT
Terminated Phase 2 Interventional Results available

Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)

NCT03768505
View directory record Official record
Conditions
Follicular Lymphoma (FL), Non Hodgkin Lymphoma, Marginal Zone Lymphoma
Interventions
Zandelisib (ME-401)
Drug
Lead sponsor
MEI Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
34
States / cities
Tucson, Arizona • Anaheim, California • Beverly Hills, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced Oct 29, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Results available

Randomized Controlled Trial of Calcitriol vs. Placebo Among Critically-ill Patients With Sepsis

NCT01689441
View directory record Official record
Conditions
Severe Sepsis or Septic Shock
Interventions
Calcitriol, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Oct 29, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis

NCT00979654
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Sifalimumab
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
24
States / cities
Anniston, Alabama • Scottsdale, Arizona • San Leandro, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Oct 29, 2026, 5:06 AM EDT
Recruiting Phase 1 Interventional

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

NCT06508463
View directory record Official record
Conditions
Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Anaplastic Large Cell Lymphoma, Mycosis Fungoides, Relapsed Anaplastic Large Cell Lymphoma, Relapsed Mycosis Fungoides
Interventions
Biopsy, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography, Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter, Single Photon Emission Computed Tomography, Cemiplimab, Ruxolitinib
Procedure · Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 29, 2026, 5:06 AM EDT
Completed Not applicable Interventional Results available

Impact of Heart Rate Characteristics Monitoring in Neonates

NCT00307333
View directory record Official record
Conditions
Sepsis
Interventions
HeRO heart rate characteristics monitor
Device
Lead sponsor
University of Virginia
Other
Eligibility
1 Day to 32 Weeks
Enrollment
3,003 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
8
States / cities
Birmingham, Alabama • Miami, Florida • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 27, 2013 · Synced Oct 29, 2026, 5:06 AM EDT
Completed Not applicable Interventional

Memantine in Systemic Lupus Erythematosus

NCT00181298
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Memantine, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 7, 2008 · Synced Oct 29, 2026, 5:06 AM EDT
Terminated Phase 1 Interventional

Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO

NCT03790852
View directory record Official record
Conditions
Wet Age-related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
KSI-301
Drug
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
21 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
Phoenix, Arizona • Beverly Hills, California • Mountain View, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 29, 2026, 5:06 AM EDT
Completed Phase 1 Interventional

Pain Catastrophizing as a Cause for Systemic Inflammation

NCT00823147
View directory record Official record
Conditions
Musculoskeletal Pain
Interventions
Pain Catastrophizing Induction
Behavioral
Lead sponsor
Beth Darnall, PhD
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 29, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Results available

Ubiquinol (Reduced COQ10) for Patients With Sepsis

NCT01948063
View directory record Official record
Conditions
Sepsis
Interventions
Ubiquinol, Placebo
Drug · Dietary Supplement
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Oct 29, 2026, 5:06 AM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

NCT01803321
View directory record Official record
Conditions
Systemic Juvenile Idiopathic Arthritis
Interventions
rilonacept (IL-1 Trap), Placebo
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
4 Years to 20 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
9
States / cities
Los Angeles, California • Wilmington, Delaware • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Oct 29, 2026, 5:06 AM EDT
Completed Phase 4 Interventional Results available

GM-CSF for Reversal of immunopAralysis in pediatriC sEpsis-induced MODS Study

NCT03769844
View directory record Official record
Conditions
Pediatric Sepsis-induced MODS
Interventions
GM-CSF
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Up to 17 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 29, 2026, 5:06 AM EDT
Recruiting Phase 3 Interventional

Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)

NCT06711887
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Ianalumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
Orchard Park, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 29, 2026, 5:06 AM EDT
Completed Not applicable Interventional

Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer

NCT03268993
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Head and Neck Carcinoma, Head and Neck, Tobacco-Related Carcinoma, Carcinoma in Situ, Dysplasia, Hyperplasia, Premalignant Lesion
Interventions
Avmacol
Dietary Supplement
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 29, 2026, 5:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Ascorbic Acid (Vitamin C) Infusion in Human Sepsis

NCT01434121
View directory record Official record
Conditions
Sepsis, Septic Shock, Hypotension, Acute Lung Injury
Interventions
Ascorbic Acid, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 1, 2018 · Synced Oct 29, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Results available

Study of VIB7734 for the Treatment of Moderate to Severely Active SLE

NCT04925934
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
VIB7734, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
17
States / cities
Upland, California • Clearwater, Florida • Ormond Beach, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Oct 29, 2026, 5:06 AM EDT
Completed Not applicable Interventional

Omega-3 Replacement With Krill Oil in Disease Management of SLE

NCT03626311
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
AKBM-3031, Placebo
Dietary Supplement · Other
Lead sponsor
Aker BioMarine Human Ingredients AS
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
15
States / cities
Birmingham, Alabama • Beverly Hills, California • Orange, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 29, 2026, 5:06 AM EDT
Terminated Not applicable Interventional Results available

Tailoring Maintenance Therapy to Cluster of Differentiation 5 Positive (CD5+) Regulatory B Cell Recovery in ANCA Vasculitis

NCT03906227
View directory record Official record
Conditions
ANCA Associated Vasculitis
Interventions
ENUMERATION OF CD5+ B Cells
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 29, 2026, 5:06 AM EDT
Recruiting No phase listed Observational

Primary Tumor Research and Outcomes Network

NCT02790983
View directory record Official record
Conditions
Spinal Column Tumor
Interventions
Not listed
Lead sponsor
AO Innovation Translation Center
Other
Eligibility
Not listed
Enrollment
1,350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 29, 2026, 5:06 AM EDT
Completed No phase listed Observational

HostDx Sepsis in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections: a Multicenter Pilot Study

NCT03744741
View directory record Official record
Conditions
Respiratory Tract Infections, Urinary Tract Infections, Skin and Soft Tissue Infections, Intraabdominal Infections, Sepsis
Interventions
HostDx Sepsis
Diagnostic Test
Lead sponsor
Inflammatix
Industry
Eligibility
18 Years and older
Enrollment
585 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Atlanta, Georgia • Lexington, Kentucky • Springfield, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 29, 2026, 5:06 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Estrogen and Gender Biased Autoimmunity

NCT00519454
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Peripheral lab draws
Other
Lead sponsor
The Center for Rheumatic Disease, Allergy, & Immunology
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2013
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 8, 2010 · Synced Oct 29, 2026, 5:06 AM EDT